Piper Jaffray Companies reaffirmed their sell rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report released on Friday morning. The brokerage currently has a $12.00 price target on the specialty pharmaceutical company’s stock.
VRX has been the topic of a number of other research reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a report on Sunday, July 30th. Cantor Fitzgerald set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a buy rating in a report on Tuesday, October 31st. BidaskClub lowered shares of Valeant Pharmaceuticals International from a buy rating to a hold rating in a report on Monday, July 31st. TD Securities upgraded shares of Valeant Pharmaceuticals International from a hold rating to a buy rating and set a $20.00 target price on the stock in a report on Tuesday. Finally, Vetr upgraded shares of Valeant Pharmaceuticals International from a strong sell rating to a sell rating and set a $13.68 target price on the stock in a report on Friday, October 6th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $17.17.
Valeant Pharmaceuticals International (VRX) traded up $0.03 on Friday, hitting $15.38. 19,959,000 shares of the company were exchanged, compared to its average volume of 17,998,627. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $18.71. The firm has a market cap of $5,350.89, a price-to-earnings ratio of 2.50, a PEG ratio of 0.43 and a beta of -0.40.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a net margin of 15.35% and a return on equity of 51.56%. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the prior year, the business posted ($0.88) EPS. The firm’s revenue was down 7.7% compared to the same quarter last year. sell-side analysts predict that Valeant Pharmaceuticals International will post 3.74 earnings per share for the current fiscal year.
WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Receives “Sell” Rating from Piper Jaffray Companies” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/valeant-pharmaceuticals-international-inc-vrx-receives-sell-rating-from-piper-jaffray-companies.html.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.87% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. boosted its holdings in Valeant Pharmaceuticals International by 118.2% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 4,512 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Valeant Pharmaceuticals International by 33.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the period. Financial Architects Inc boosted its holdings in Valeant Pharmaceuticals International by 10.5% in the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares during the period. Cetera Investment Advisers bought a new position in Valeant Pharmaceuticals International in the 2nd quarter valued at $192,000. Finally, IPG Investment Advisors LLC bought a new position in Valeant Pharmaceuticals International in the 2nd quarter valued at $203,000. 49.74% of the stock is owned by institutional investors.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.